# S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer

> **NCT00134095** · PHASE2 · UNKNOWN · sponsor: **Fukushima Medical University Hospital** · enrollment: 70 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** irinotecan hydrochloride
- **DRUG:** tegafur-gimeracil-oteracil potassium
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00134095
- **Lead sponsor:** Fukushima Medical University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-09
- **Primary completion:** 2008-08
- **Final completion:** —
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2013-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00134095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00134095, "S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00134095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*